person · Reporting owner
Lundbeckfond Invest A/S
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | Director · 10% owner | August 09, 2023 | August 12, 2023 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | 10% owner | November 01, 2017 | November 01, 2017 |
| scPharmaceuticals Inc.SCPH · Entity 74456 | 10% owner | November 21, 2017 | November 21, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date August 09, 2023 · Filed August 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,950,686 |
Reported balance
After 2023-08-09 transaction · row 1
1 source rowRow 1 · 2023-08-09 · Grant · Acquired 7,901,234 · Balance 13,950,686 |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 | Direct | 7,901,234 |
Reported balance
After 2023-08-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-09 · Grant · Acquired 7,901,234 · Balance 7,901,234 F1: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023). |
Filing footnotes · ownership attribution and instrument terms
F1: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023).
Spero Therapeutics, Inc.
Report date November 01, 2017 · Filed November 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-11-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Series A preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-11-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: The shares of Series B preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-11-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F4: The shares of Series C preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series A preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F2: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.
F3: The shares of Series B preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F4: The shares of Series C preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
scPharmaceuticals Inc.
Report date November 21, 2017 · Filed November 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,183,986 |
Ending reported balance
After 2017-11-21 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-11-21 · Conversion · Acquired 1,544,858 · Balance 1,544,858 F1: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. Row 2 · 2017-11-21 · Conversion · Acquired 984,366 · Balance 2,529,224 F2: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. Row 3 · 2017-11-21 · Purchase · Acquired 654,762 · Balance 3,183,986 |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-11-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-11-21 · Conversion · Disposed 11,092,383 · Balance 0 F3: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-11-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-11-21 · Conversion · Disposed 7,067,945 · Balance 0 F3: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
F2: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
F3: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Enliven Therapeutics, Inc.
Report date March 16, 2020 · Filed March 16, 2020
Section 16 reporting ended · disclosed 2020-03-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,432,722 |
Ending reported balance
After 2020-03-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-16 · Conversion · Acquired 1,245,222 · Balance 1,245,222 F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Row 2 · 2020-03-16 · Purchase · Acquired 187,500 · Balance 1,432,722 |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-16 · Conversion · Disposed 478,749 · Balance 0 F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-03-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-16 · Conversion · Disposed 5,470,492 · Balance 0 F2: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-03-16 · Conversion · Disposed 1,894,444 · Balance 0 F3: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F3: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Lexeo Therapeutics, Inc.
Report date November 07, 2023 · Filed November 10, 2023
Section 16 reporting ended · disclosed 2023-11-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,835,959 |
Ending reported balance
After 2023-11-07 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-11-07 · Conversion · Acquired 1,321,474 · Balance 1,321,474 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. Row 2 · 2023-11-07 · Conversion · Acquired 287,213 · Balance 1,608,687 F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. Row 3 · 2023-11-07 · Purchase · Acquired 227,272 · Balance 1,835,959 |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-11-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-07 · Conversion · Disposed 13,999,999 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-11-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-07 · Conversion · Disposed 2,615,533 · Balance 0 F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
Trevi Therapeutics, Inc.
Report date May 09, 2019 · Filed May 13, 2019
Section 16 reporting ended · disclosed 2019-05-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,151,544 |
Ending reported balance
After 2019-05-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-05-09 · Conversion · Acquired 776,544 · Balance 776,544 F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Row 2 · 2019-05-09 · Purchase · Acquired 375,000 · Balance 1,151,544 |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-09 · Conversion · Disposed 6,849,315 · Balance 0 F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2023 Filed Nov 10, 2023 01:33 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | ConversionSeries B convertible preferred stock · Derivative | 2,615,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054907 · doc4.xml · derivative · entry 5 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 287,213 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2 · price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. Read SEC document |
| November 07, 2023 Filed Nov 10, 2023 01:33 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | ConversionSeries A convertible preferred stock · Derivative | 13,999,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054907 · doc4.xml · derivative · entry 4 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,321,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. Read SEC document |
| November 07, 2023 Filed Nov 10, 2023 01:33 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | PurchaseCommon Stock | 227,272 | $11.00 | $2,499,992.00 |
DisclosureSEC source: 0001209191-23-054907 · doc4.xml · nonDerivative · entry 3 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,835,959 Read SEC document |
| November 07, 2023 Filed Nov 10, 2023 01:33 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | ConversionCommon Stock | 287,213 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054907 · doc4.xml · nonDerivative · entry 2 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,608,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. Read SEC document |
| November 07, 2023 Filed Nov 10, 2023 01:33 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | ConversionCommon Stock | 1,321,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054907 · doc4.xml · nonDerivative · entry 1 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,321,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. Read SEC document |
| August 09, 2023 Filed Aug 12, 2023 01:22 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantWarrants (Right to Buy) · Derivative | 7,901,234 | $0.13 Strike: $2.47 | $987,654.25 |
DisclosureSEC source: 0001140361-23-039344 · form4.xml · derivative · entry 2 Lundbeckfond Invest A/S · CIK 0001591046 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,901,234 Underlying: Common Stock · 7,901,234 shares Expires not disclosed F1 · derivative.expiration_date: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023). Read SEC document |
| August 09, 2023 Filed Aug 12, 2023 01:22 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantCommon Stock | 7,901,234 | $1.90 | $15,012,344.60 |
DisclosureSEC source: 0001140361-23-039344 · form4.xml · nonDerivative · entry 1 Lundbeckfond Invest A/S · CIK 0001591046 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,950,686 Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionSeries C Preferred Stock · Derivative | 150,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037653 · form4.xml · derivative · entry 5 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,892,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F2 · derivative.exercise_date: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F2 · derivative.expiration_date: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionSeries B Preferred Stock · Derivative | 219,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037653 · form4.xml · derivative · entry 4 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,014,161 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 2,142,857 | $14.00 | $29,999,998.00 |
DisclosureSEC source: 0001140361-21-037653 · form4.xml · nonDerivative · entry 3 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,049,452 Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionCommon Stock | 1,892,434 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-037653 · form4.xml · nonDerivative · entry 2 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,906,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionCommon Stock | 2,014,161 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-037653 · form4.xml · nonDerivative · entry 1 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,014,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:07 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries B Preferred Stock · Derivative | 1,894,444 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008479 · doc4.xml · derivative · entry 5 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.exercise_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.expiration_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:07 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries A Preferred Stock · Derivative | 5,470,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008479 · doc4.xml · derivative · entry 4 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 868,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:07 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries Seed Preferred Stock · Derivative | 478,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008479 · doc4.xml · derivative · entry 3 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,003 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:07 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | PurchaseCommon Stock | 187,500 | $16.00 | $3,000,000.00 |
DisclosureSEC source: 0000899243-20-008479 · doc4.xml · nonDerivative · entry 2 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,432,722 Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:07 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionCommon Stock | 1,245,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008479 · doc4.xml · nonDerivative · entry 1 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,245,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | ConversionSeries C Preferred Stock · Derivative | 6,849,315 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013250 · doc4.xml · derivative · entry 3 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 776,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | PurchaseCommon Stock | 375,000 | $10.00 | $3,750,000.00 |
DisclosureSEC source: 0000899243-19-013250 · doc4.xml · nonDerivative · entry 2 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,544 Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | ConversionCommon Stock | 776,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-013250 · doc4.xml · nonDerivative · entry 1 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:24 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries B Preferred Stock · Derivative | 7,067,945 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027197 · doc4.xml · derivative · entry 5 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 984,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. F3 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. F3 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. F3 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:24 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries A Preferred Stock · Derivative | 11,092,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027197 · doc4.xml · derivative · entry 4 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,544,858 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. F3 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. F3 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. F3 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:24 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | PurchaseCommon Stock | 654,762 | $14.00 | $9,166,668.00 |
DisclosureSEC source: 0000899243-17-027197 · doc4.xml · nonDerivative · entry 3 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,183,986 Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:24 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 984,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027197 · doc4.xml · nonDerivative · entry 2 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,529,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:24 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 1,544,858 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027197 · doc4.xml · nonDerivative · entry 1 Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,544,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.